Business Context and Reporting Period
Company: McKesson Corporation (McKesson)
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2002
Reporting Period: The filing primarily serves to make available the press release regarding results for the third quarter ended December 31, 2001 (incorporated by reference as Exhibit 99.1). The filing also provides an update on legal proceedings in connection with a proposed debt offering.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the press release (Exhibit 99.1) referenced in the filing but are not reproduced in the provided text.
Environmental Liabilities: The Company estimates reasonably possible remediation costs for five former chemical business sites at approximately $13 million (net of third-party contributions). Additionally, estimated liability for 21 Superfund sites is approximately $1.5 million. These amounts are included in recorded environmental liabilities as of March 31, 2001.
Material Changes and Legal Proceedings
The filing details extensive litigation related to the restatement of financial statements for the former HBOC unit (Information Solutions segment) due to improper revenue recording in 1999.
- Accounting Litigation Status: As of January 15, 2002, 87 lawsuits have been filed. Sixty-six are federal actions, largely consolidated in the Northern District of California. Twenty-one are state actions.
- Recent Federal Developments: On January 7, 2002, the court dismissed claims against McKesson under Section 10(b) based on pre-merger conduct and Section 14(a) claims, granting plaintiffs leave to amend. Claims based on post-merger statements remain pending against McKesson. On January 9, 2002, McKesson's counterclaim against former HBOC shareholders for "unjust enrichment" was dismissed with prejudice.
- Regulatory Investigations: On January 3, 2002, the SEC notified McKesson that its investigation of the Company has been terminated and no enforcement action was recommended. However, criminal and civil actions against former officers (including Dominick DeRosa, Jay P. Gilbertson, and Albert J. Bergonzi) continue or have resulted in settlements.
- Other Litigation:
- Antitrust: Approximately 109 federal actions (MDL 997) regarding pharmaceutical pricing are pending. Summary judgment was granted to wholesalers, but plaintiffs have appealed. State cases in California and Mississippi are pending.
- FoxMeyer Litigation: Settled on December 6, 2001, with no material impact on the Company.
- Product Liability: Pending cases regarding diet drugs (fenfluramine/phentermine) and latex gloves are being indemnified by manufacturers or covered by insurance. A patent infringement suit regarding bar code technology is stayed pending other litigation.
Guidance, Outlook, and Risks
Outlook on Litigation: Management states it is not feasible to predict the outcome or estimate the potential range of loss regarding the accounting litigation. The timing of resolution is uncertain.
Risks: The Company warns that resolutions could include judgments or settlements requiring substantial payments, which could have a material adverse impact on financial position, results of operations, and cash flows.
Environmental Risk: Potential costs related to environmental matters are uncertain due to evolving laws, cleanup technologies, and liability determinations.
Investor Verification Checklist
- Review the press release (Exhibit 99.1) for specific Q3 2001 financial results (revenue, earnings, cash flow) not included in this text.
- Monitor the status of the consolidated securities litigation in the Northern District of California, specifically the amended complaints following the January 7, 2002 dismissal orders.
- Verify the status of the antitrust appeals in the Seventh Circuit regarding MDL 997.
- Confirm the final terms of the FoxMeyer settlement and ensure no residual liabilities exist.
- Assess the potential impact of the $13 million environmental liability estimate on future cash flows.